Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Kiladjian, 2016, Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone, Leukemia, 30, 776, 10.1038/leu.2015.326 How J., Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel). 2020;12(7):1–13. doi:10.3390/cancers12071954. Gisslinger, 2020, Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and continuation-PV): a randomised, non-inferiority, phase 3 trial and its extension study, Lancet Haematol, 7, 10.1016/S2352-3026(19)30236-4 Gisslinger, 2020, Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension, Am. Soc. Haematol. Barbui, 2021, Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial, Lancet Haematol, 8, 10.1016/S2352-3026(20)30373-2 Ropeginterferon alfa-2b (P1101) vs. anagrelide in essential thrombocythemia patients with hydroxyurea resistance or intolerance - full text view - clinicaltrials.gov. Accessed March 13, 2021. https://clinicaltrials.gov/ct2/show/NCT04285086. Paper: ropeginterferon demonstrates safety and efficacy in myelofibrosis: Pilot Study Results. Accessed March 13, 2021. https://ash.confex.com/ash/2020/webprogram/Paper138934.html.